| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Topline Data Readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Topline Data Readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Topline Data Readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
Aclaris Therapeutics, Inc.$5.58
-0.21 (-3.68%)
C 50Pipeline Score Fair Value Pharma · Commercial
Market Cap
646.64 M
EPS
-0.56
P/E Ratio
-8.26 $
Value Trade
7.12 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
2.00 M
R&D Expenses
15.66 M
Operating CF
-18.15 M
Total Assets
198.72 M
Total Liabilities
55.07 M
Equity
143.65 M
D/E Ratio
12,345
-3.83 %
Week
7.62 %
1 Month
41.25 %
3 Month
93 %
6 Month
-80.08 %
5 Year
-62.14 %
All Time
Cash Data
Cash Position
105.42 M
Monthly Burn
6.05 M
Runway
15.5 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.40 M
52 Week Range
1.34 - 5.15
% held by Insiders
18.38 %
% held by Institutions
66.68 %
Enterprise Value
543.21 M
Total Shares
139.66 M
Short %
9.4 %
Float Shares
121.37 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aclaris Therapeutics, Inc.
589Total events
6Upcoming
145Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 6
Sep 17, 2026
T2Oral Presentation
Presentation at European Academy of Dermatology and Venereology September 17, 2026
Event history 583
Q3 2026
◆Topline ReadoutATI-052Clinical Data
Topline results expected from Phase 1b atopic dermatitis trial
atopic dermatitissource ↗
Q3 2026
◆Trial InitiationATI-2138Trial
Initiate Phase 2b trial for ATI-2138 in Lichen Planus
Lichen Planussource ↗
Q3 2026
◆Trial InitiationATI-052Trial
Phase 2b program initiation expected
asthma and atopic dermatitissource ↗
Jun 4, 2026
◆Oral PresentationPresentation
Aclaris Therapeutics to participate in fireside chat at 2026 Jefferies Global Healthcare Conference
May 14, 2026
◆Oral PresentationPresentation
Corporate presentation at 2026 Bank of America Healthcare Conference
May 7, 2026
▲Full ResultsATI-052Clinical Data
Full top line results from Phase 1a SAD/MAD trial of ATI-052
healthy volunteerssource ↗
Apr 28, 2026
▲Full ResultsATI-052Clinical Data
Positive full top line results from Phase 1a SAD/MAD trial of ATI-052
Healthy Volunteerssource ↗
Apr 28, 2026
◆Pipeline PrioritizationATI-2138Corporate
Lead indication selection for ATI-2138
immuno-inflammatory diseasessource ↗
Apr 28, 2026
●Oral PresentationPresentation
Management conference call to discuss ATI-052 results and ATI-2138 program
Apr 28, 2026
◆Enrollment UpdateATI-052Trial
Enrollment ongoing in Phase 1b atopic dermatitis trial
Atopic Dermatitissource ↗
Apr 14, 2026
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Drug Pipeline Intelligence
C50
Pipeline Score $1.4B
Pipeline ValueFair Value
Valuation Signal14
Drugs Scored2.1x
rNPV / MCap Top 76%
Micro Cap (rank 220 of 911)
Percentile RankAclaris Therapeutics, Inc. carries a moderate pipeline score (50/100), with $4.9B risk-adjusted pipeline value, led by ATI-2138 in Atopic Dermatitis (Phase 2), across $116B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATI-045 Small molecule | Atopic Dermatitis | Phase 2 | NCT07011706 | 17% | $748M | ACTIVE NOT_RECRUITING | 110 | AVERAGE | B (68) | Oct 1, 2026 | MODERATE_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ATI-052 | — | Phase 1a | 2026-05-07 | The Phase 1a SAD/MAD trial of ATI-052 demonstrated a best-in-class pharmacokinetic/pharmacodynamic profile with an extended dosing schedule of up to every three months, exceeding Aclaris' target profile for the drug's efficacy. Read More | Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Validating Poten Read More | |
ATI-052 | — | Phase 1a | 2026-05-07 | The Phase 1a SAD/MAD trial of ATI-052 demonstrated a best-in-class pharmacokinetic/pharmacodynamic profile with an extended dosing schedule of up to every three months, exceeding Aclaris' target profile for the drug's efficacy. Read More | Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Validating Poten Read More | |
ATI-052 | — | Phase 1a | 2026-05-07 | The Phase 1a SAD/MAD trial of ATI-052 demonstrated a best-in-class pharmacokinetic/pharmacodynamic profile with an extended dosing schedule of up to every three months, exceeding Aclaris' target profile for the drug's efficacy. Read More | Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Validating Poten Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ACRS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ACRS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ACRSAclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Aclaris Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference on June 4, 2026. CEO Dr. Neal Walker and the senior leadership team will engage in a fireside chat. The event will be accessible via a live and archived webcast on Aclaris' website for at least 30 days.
Read more →ACRSAclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) will participate in the 2026 Bank of America Healthcare Conference held on May 14, 2026. Dr. Hugh Davis, the President and COO, is scheduled to present at 9:35 AM PT. The event will be accessible via a live and archived webcast on the Aclaris website for at least 30 days following the conference. Aclaris focuses on developing treatments for immuno-inflammatory diseases, which are often inadequately addressed by current options.
Read more →ACRSAclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Validating Poten
Aclaris Therapeutics reported its financial results for Q1 2026, highlighting progress in its clinical trials and corporate developments. The company announced successful results from its Phase 1a SAD/MAD trial for ATI-052, which exceeded expectations and reinforced its potential as a best-in-class treatment. Financially, Aclaris experienced a net loss of $19.8 million while generating $2.0 million in total revenue, primarily due to increased royalties. Additionally, the company has a solid cash position projected to support its operational needs through 2028.
Read more →ACRSAclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
Aclaris Therapeutics announced positive results from its Phase 1a trial of ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, indicating a strong safety and efficacy profile. The company also selected lichen planus as the lead indication for ATI-2138, an oral ITK/JAK3 inhibitor. Future studies for both compounds are planned, with results expected in the coming years.
Read more →ACRSAclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
Aclaris Therapeutics will present results from its Phase 1a trial of ATI-052 and the lead indication selection for ATI-2138 on April 28, 2026. The announcement will precede a conference call and webcast scheduled for 8:30 AM EST. This update highlights Aclaris' commitment to developing treatments for immuno-inflammatory diseases.
Read more →ACRSClinical Pipeline Update: ATI-052: Full SAD MAD Results ATI-2138: Potential Mechanistically Complete Therapy for Lichen Planus
ATI-052 has shown promising results in recent clinical trials, demonstrating significant potency compared to existing treatments for conditions like atopic dermatitis and asthma. The drug exhibits a favorable pharmacokinetic and pharmacodynamic profile, allowing for sustained inhibition of key inflammatory mediators. Furthermore, a positive safety profile with minimal adverse events has been observed, supporting the continuation of clinical development. Future trials for ATI-052 are planned, aiming to establish its efficacy and safety in broader patient populations.
Read more →ACRS▲ +5.3%on this news
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Aclaris Therapeutics, Inc. will participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026, at 12:00 PM EDT. The event will feature CEO Dr. Neal Walker and senior leadership discussing the company's initiatives and research. A live webcast of the conference will be available on Aclaris' website, along with an archived version accessible for at least 30 days. This participation highlights Aclaris' commitment to addressing treatment gaps in immuno-inflammatory diseases.
Read more →ACRSResults Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
Aclaris Therapeutics presented positive results from its Phase 2a trial of ATI-2138 at the 2026 AAD Annual Meeting. The trial showed significant improvements in disease severity, itch, and quality of life for patients with moderate-to-severe atopic dermatitis. ATI-2138, a selective oral inhibitor, was well tolerated and demonstrated a strong mechanistic rationale for its use in immuno-inflammatory diseases.
Read more →ACRSAclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Aclaris Therapeutics announced that an ePoster detailing results from its Phase 2a trial of ATI-2138 will be available at the 2026 American Academy of Dermatology Annual Meeting. The trial focuses on patients with moderate-to-severe atopic dermatitis and showcases data that has not been previously reported. ATI-2138 is a potent investigational oral covalent inhibitor targeting interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3). Aclaris aims to address the needs of patients who lack satisfactory treatment options for immuno-inflammatory diseases.
Read more →ACRS▼ -5.7%on this newsshared move
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
Aclaris Therapeutics has successfully completed patient enrollment in its Phase 2 trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis. The trial is randomized, double-blind, and placebo-controlled, aiming to evaluate the drug's efficacy and safety in 109 participants. Top-line results are anticipated in the fourth quarter of 2026. Bosakitug targets the thymic stromal lymphopoietin (TSLP) pathway, which is significant in managing inflammatory responses in atopic dermatitis.
Read more →ACRSAclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference
Aclaris Therapeutics will participate in the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026. CEO Dr. Neal Walker and the senior leadership team will engage in a fireside chat. The event will be webcast live and archived on Aclaris' website for at least 30 days, promoting their focus on immuno-inflammatory diseases.
Read more →ACRS▼ -5.4%on this newsshared move
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics reported its financial results for Q4 and full year 2025, highlighting strong execution in its pipeline. The company announced positive interim results for ATI-052 and initiated two Phase 1b trials. Despite a decrease in revenue, Aclaris maintains a solid cash position, expected to fund operations into 2028, with several key milestones anticipated in 2026.
Read more →ACRSAclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
Aclaris Therapeutics has launched a Phase 1b proof-of-concept trial for ATI-052, a bispecific antibody targeting asthma. This follows positive interim results from a previous trial in atopic dermatitis. The trial will assess safety and efficacy in approximately 16 patients, with top-line results expected in late 2026. Aclaris plans to initiate a Phase 2b program for both conditions thereafter.
Read more →ACRSAclaris Therapeutics to Participate in Two February Healthcare Conferences
Aclaris Therapeutics, Inc. announced its participation in two healthcare conferences in February 2026. The events will feature live and archived webcasts accessible on their website for at least 30 days. Aclaris is dedicated to developing innovative treatments for patients with immuno-inflammatory diseases.
Read more →ACRSAclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
Aclaris Therapeutics announced positive preclinical results for its ITK/JAK3 inhibitor, ATI-2138, showing rapid and sustained hair regrowth in a murine model of severe alopecia areata. The study, conducted by Dr. Angela Christiano, indicated that ATI-2138 outperformed ritlecitinib. The company plans to initiate a Phase 2b trial in the first half of 2026.
Read more →ACRSAclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
Aclaris Therapeutics has commenced a Phase 1b proof-of-concept trial for its investigational bispecific antibody, ATI-052, targeting atopic dermatitis. This follows positive interim results from the Phase 1a trial, showcasing safety and pharmacokinetics. The trial aims to evaluate safety and efficacy in patients with moderate-to-severe atopic dermatitis. Further, a second Phase 1b trial in asthma is anticipated to launch soon. Top-line results from both studies are expected in the latter half of 2026.
Read more →ACRSCorporate Overview January 2026 EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION 2 Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that t
ACRS is advancing its therapy ATI-2138, which has shown promising clinical results in the treatment of immuno-inflammatory diseases such as atopic dermatitis. The therapy demonstrated significant reductions in inflammation and improved patient outcomes during Phase 2a trials. A robust pipeline is in place with additional studies set to begin in 2026, including indications for conditions like alopecia and asthma. ACRS's financial strength and commitment to innovation further support its potential in the biopharma sector.
Read more →ACRSAclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4R Bispecific Antibody ATI-052 Supporting Expedited Clinical Development - Positive Interim Results of Phase 1a Single (SAD) and M
Aclaris Therapeutics has announced positive interim results from its Phase 1a trial of the bispecific antibody ATI-052, indicating a strong safety and potency profile. The results support expedited clinical development, with Phase 1b proof-of-concept trials in atopic dermatitis and asthma planned for early 2026. The company aims to initiate a Phase 2b trial in atopic dermatitis later the same year. These developments reinforce the potential of ATI-052 as a best-in-class treatment for inflammatory diseases.
Read more →ACRSAclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
Aclaris Therapeutics, Inc. has been officially added to the Nasdaq Biotechnology Index effective December 19, 2025. This inclusion reflects the company's compliance with the index's eligibility requirements, showcasing its growth in the biopharmaceutical sector. Aclaris is dedicated to developing innovative treatments for immuno-inflammatory diseases, enhancing its visibility in the market.
Read more →ACRSAclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Aclaris Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. CEO Dr. Neal Walker and senior leadership will engage in a fireside chat in New York City. A live and archived webcast will be available on Aclaris' website for at least 30 days, enhancing public access to the discussion.
Read more →ACRSAclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics reported its third quarter 2025 financial results, highlighting positive outcomes from the Phase 2a trial of ATI-2138. The company reiterated timelines for ongoing trials and announced plans for new Phase 1b trials in asthma and atopic dermatitis. Despite an increase in net loss and a decrease in revenue, Aclaris maintains a strong cash position to support its operations through 2028.
Read more →ACRSAclaris Therapeutics to Participate in Three November Healthcare Conferences
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in three healthcare conferences scheduled for November. The events will feature live and archived webcasts accessible on their website. Aclaris is dedicated to developing innovative treatments for patients with immuno-inflammatory diseases.
Read more →ACRS▼ -5.2%on this news
Patient Focused Innovation Developing Therapeutic Franchises to Address Gaps in Important I&I Diseases 2025 R&D Day
Aclaris Therapeutics presented its 2025 R&D Day, discussing its pipeline and upcoming clinical milestones. Key highlights include the potential of Bosakitug for atopic dermatitis and the initiation of Phase 2 studies for ATI-2138 in new indications such as Lichen Planus. The company anticipates significant data readouts in 2026 and aims to expand its therapeutic portfolio strategically. Aclaris emphasized its strong financial position, which supports its research and partnership strategies moving forward.
Read more →ACRSAclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
Aclaris Therapeutics will host its 2025 R&D Day in New York on October 14, 2025, focusing on innovations in immuno-inflammatory diseases. The event will feature presentations from Aclaris leadership and expert speakers, discussing the company's progress and therapeutic gaps in the market. A live Q&A session will follow the presentations.
Read more →ACRSAclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
Aclaris Therapeutics announced that a late-breaking abstract on its Phase 2a trial of ATI-2138 will be presented at the 2025 EADV Congress. The investigational drug, targeting atopic dermatitis, has shown promising efficacy and safety in preliminary studies. The presentation will provide additional insights into the trial results, highlighting the potential of ATI-2138 in treating inflammatory diseases.
Read more →ACRSAclaris Therapeutics to Participate in Two September Healthcare Conferences
Aclaris Therapeutics, Inc. has announced its participation in two upcoming healthcare conferences in September 2025. The company's CEO, Dr. Neal Walker, will engage in a fireside chat at the Cantor Global Healthcare Conference on September 3 and deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9. Both events will have webcasts available for live and subsequent viewing for at least 30 days on the Aclaris website.
Read more →ACRSAclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Ef
Aclaris Therapeutics has reported its financial results for the second quarter of 2025 alongside a corporate update. The company has achieved positive results in its Phase 2a trial of the ITK/JAK3 inhibitor ATI-2138, confirming its tolerability and efficacy. Additionally, Aclaris has advanced its anti-TSLP monoclonal antibody, bosakitug, into a Phase 2 trial for atopic dermatitis. Despite some financial losses and revenue declines, the company expects to have sufficient funds to operate into the second half of 2028.
Read more →ACRSAclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
Aclaris Therapeutics announced positive top-line results from its Phase 2a trial of ATI-2138, an investigational inhibitor of ITK and JAK3, in patients with moderate-to-severe atopic dermatitis. The trial met its primary and key secondary endpoints, confirming a favorable tolerability profile and comparable efficacy to existing therapies. Aclaris plans to further develop ATI-2138 for alopecia areata and other indications.
Read more →ACRS▼ -7.7%on this newsshared move
ATI-2138 Phase 2a Top-Line Results
Aclaris has reported positive top-line results from their Phase 2a open-label trial of ATI-2138 for alopecia areata. The treatment showed clinically meaningful improvement in itch severity for 63% of participants at week 12. Additionally, Aclaris plans to advance ATI-2138 while also exploring its potential for other indications. This success strengthens Aclaris's ITK franchise and affirms the therapeutic potential of their targeted drug development pipeline.
Read more →ACRSAclaris Therapeutics Announces Leadership Transition
Aclaris Therapeutics has appointed Dr. Roland Kolbeck as the new Chief Scientific Officer, succeeding Dr. Joe Monahan, who will transition to a Special Scientific Advisor role until March 2026. Dr. Kolbeck's extensive experience in inflammation and antibody development is expected to enhance Aclaris' pipeline of immuno-inflammatory product candidates. The leadership transition aims to strengthen the company's research and development efforts.
Read more →ACRSAclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
Aclaris Therapeutics, Inc. has been included in the Russell 2000 and Russell 3000 indexes following the 2025 annual reconstitution. This inclusion is effective from June 30, 2025, and signifies the company's growing market presence. The Russell indexes are significant benchmarks for investment managers, with over $10 trillion in assets tied to them.
Read more →ACRSCorporate Overview June 2025 EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION 2 Disclaimer and Cautionary Note Regarding Forward -Looking Statements Any statements contained in this presentation that do not describe hi
Aclaris Therapeutics (ACRS) has presented an overview of its corporate strategy highlighting its commitment to developing innovative treatments for immuno-inflammatory diseases. The company boasts a robust pipeline with several therapeutic programs progressing towards clinical development. Aclaris has significant financial resources, with $190.5 million in cash expected to support operations through the first half of 2028. Multiple milestones in drug development are anticipated in 2025 and 2026, particularly with their promising candidate ATI-2138, aimed at treating conditions such as atopic dermatitis, alopecia areata, and more.
Read more →ACRS▼ -5.8%on this newsshared move
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
Aclaris Therapeutics, Inc. will present at the H.C. Wainwright Inflammation & Immunology Virtual Conference on June 30, 2025. The presentation will be accessible via a live and archived webcast on their website. Aclaris is dedicated to developing innovative treatments for patients with immuno-inflammatory diseases.
Read more →ACRSAclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
Aclaris Therapeutics has launched a Phase 1a/1b clinical trial program for ATI-052, an investigational bispecific antibody targeting TSLP and IL-4R, after receiving IND clearance from the FDA. The trial aims to evaluate the safety and pharmacokinetics of ATI-052 in healthy volunteers. Aclaris anticipates completion of the Phase 1a portion by the end of 2025, with top-line results expected in early 2026. Given its design, ATI-052 may provide enhanced therapeutic benefits for immune-mediated diseases compared to traditional monoclonal antibodies.
Read more →ACRSAclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
Aclaris Therapeutics has commenced a Phase 2 trial for bosakitug (ATI-045) targeting moderate-to-severe atopic dermatitis, building on positive Phase 2a results. The trial aims to evaluate efficacy and safety across approximately 90 patients, with top line results expected in 2026. Bosakitug is noted for its superior potency and ability to bind thymic stromal lymphopoietin (TSLP), offering promise as a significant treatment option for the condition.
Read more →ACRS▲ +11%on this newsshared move
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its participation in two upcoming healthcare conferences in June 2025. The company's CEO, Dr. Neal Walker, along with the senior leadership team, will participate in a fireside chat at both the Jefferies Global Healthcare Conference in New York on June 4, and the Goldman Sachs Global Healthcare Conference in Miami on June 11. Live webcasts of both events will be available on the company's website for at least 30 days.
Read more →ACRSAclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
Aclaris Therapeutics, Inc. announced its participation in the HC Wainwright "HCW@Home" series, featuring a fireside chat with CEO Neal Walker and the leadership team. Scheduled for May 16, 2025, at 1 PM EDT, the discussion will be accessible through a live and archived webcast on Aclaris' website. This engagement highlights Aclaris' commitment to showcasing its innovative work in immuno-inflammatory disease treatments.
Read more →ACRSAclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Throu
Aclaris Therapeutics reported its financial results for Q1 2025, highlighting a cash runway projected to extend through mid-2028. The company anticipates multiple catalysts in immuno-inflammatory indications through 2025 and 2026, with the recent FDA clearance of an IND application for its bispecific antibody, ATI-052. However, the company experienced a decrease in total revenue compared to the previous year and reported a net loss. It remains focused on executing its clinical programs while exploring partnerships for further development.
Read more →ACRSAclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
Aclaris Therapeutics, Inc. has appointed Dr. Jesse Hall as Chief Medical Officer, effective May 1, 2025. Dr. Hall brings extensive experience in clinical development, particularly in immunology and antibody development, which will be crucial for Aclaris' clinical strategy. He is expected to enhance the company’s efforts in leveraging its portfolio of immuno-inflammatory product candidates. Aclaris' robust pipeline and solid cash position are highlighted as significant advantages during this transition.
Read more →ACRSAclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
Aclaris Therapeutics announced that the FDA has granted IND clearance for its investigational drug ATI-052, a bispecific anti-TSLP/IL-4R monoclonal antibody. This clearance allows the company to progress to a Phase 1a/1b clinical trial, which is expected to start in the second quarter of 2025. ATI-052 aims to target and block key inflammatory pathways linked to various immuno-inflammatory diseases. The company believes ATI-052 may be a best-in-class treatment due to its dual mechanism of action, potentially offering enhanced therapeutic efficacy.
Read more →ACRSAclaris Therapeutics to Participate in Two March Healthcare Conferences
Aclaris Therapeutics, Inc. announced its participation in two upcoming healthcare conferences in March 2025. The CEO, Dr. Neal Walker, along with the senior leadership team, will engage in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11 and the H.C. Wainwright Virtual Conference on March 27. Both events will have a live webcast available on the company's website, reflecting Aclaris' efforts to communicate its developments in immuno-inflammatory disease treatments.
Read more →ACRS▼ -7.1%on this newsshared move
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease In
Aclaris Therapeutics reported its financial results for the fourth quarter and full year of 2024, highlighting a substantial net loss that increased from the previous year. The company announced a promising pipeline with multiple clinical catalysts expected in 2025, including Phase 2 data for bosakitug in severe asthma. Despite a decrease in total revenue, Aclaris maintained a strong cash position, sufficient to fund operations into 2028. The company is actively engaged in various clinical trials, with critical data anticipated to enhance its development strategies.
Read more →ACRSAclaris Therapeutics Announces Formation of New Scientific Advisory Board
Aclaris Therapeutics has announced the establishment of a new Scientific Advisory Board, which features renowned experts in pulmonology. The board includes Dr. Marianne Mann and Dr. Zuzana Diamant, both highly regarded in their fields with vast experience in clinical research and drug development. Their expertise will be pivotal in steering Aclaris's development programs aimed at addressing immuno-inflammatory diseases. This addition reflects Aclaris's commitment to advancing novel therapeutics and enhancing its R&D efforts.
Read more →ACRSI N V E S T O R P R E S E N T A T I O N Corporate Overview January 2025 2 Disclaimer and Cautionary Note Regarding Forward-Looking Statements Any statements contained in this presentation that do not describe historical
ACRS presented a corporate overview highlighting their strong financial position and ongoing development programs targeting immuno-inflammatory diseases. Their investigational drug, ATI-2138, is positioned as a next-generation treatment with a focus on autoimmune conditions such as atopic dermatitis, alopecia areata, and more. The management outlined a robust pipeline and financial strength, expecting cash runway until at least 2028. However, they acknowledged that project timelines are subject to various uncertainties and competitive pressures remain from existing therapies.
Read more →ACRSAclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aclaris Therapeutics has announced the granting of nonstatutory stock options and restricted stock units to a new employee under its 2024 Inducement Plan. The grants, totaling 215,000 shares in options and 61,000 RSUs, were issued as part of a strategy to attract talent in accordance with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $2.48 per share, aligning with the company's stock price at the time. Vesting of the awards is contingent on the new hire's continued employment over four years.
Read more →ACRS▼ -9%on this news
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Aclaris Therapeutics, Inc. will participate in the upcoming Piper Sandler 36th Annual Healthcare Conference on December 3, 2024. Members of the management team will take part in a fireside chat to discuss the company's development of novel drug candidates for immuno-inflammatory diseases. The event will provide insight into Aclaris' initiatives and can be accessed via a webcast on their website. This participation positions the company favorably among key industry stakeholders and investors.
Read more →ACRS▲ +53.2%on this news· ran to +124% by day 1
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - Enhances Aclaris' pipeline with complementary biologics portfolio - - E
Aclaris Therapeutics has entered into an exclusive global license agreement with Biosion, Inc. for two promising biologics, BSI-045B and BSI-502, which target immunological conditions. This move is expected to strengthen Aclaris' portfolio and accelerate its transition into a leading immunology company. Alongside the Biosion deal, Aclaris has expanded its leadership team with experienced biotech executives. The company also announced a conference call to provide further insights into the agreement and its implications for their strategic growth.
Read more →ACRS▲ +53.2%on this news· ran to +124% by day 1
Aclaris Therapeutics Announces $80 Million Private Placement
Aclaris Therapeutics announced a private placement, raising $80 million by issuing 35,555,555 shares at $2.25 per share. The private placement, led by Vivo Capital, aims to fund the company's research and development efforts for its pipeline of drug candidates targeting immuno-inflammatory diseases. The closing of this financing is expected to take place on or about November 19, 2024, pending customary conditions. A registration rights agreement has been established to allow for the resale of shares sold in the private placement.
Read more →ACRSAclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced; Top-line Data Anticipated i
Aclaris Therapeutics reported its financial results for the third quarter of 2024, highlighting the onset of the Phase 2a trial for ATI-2138 aimed at atopic dermatitis. The company indicated a strong financial position with sufficient cash reserves projected to support operations through 2028. Despite the positive developments in their pipeline, Aclaris reported a considerable net loss in Q3, reflecting challenges in revenue generation compared to the previous year. Top-line data from the ongoing trial is expected in the first half of 2025.
Read more →ACRSAclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Aclaris Therapeutics has announced the dosing of the first patient in its Phase 2a clinical trial for ATI-2138, an investigational oral covalent inhibitor targeting ITK and JAK3 for moderate to severe atopic dermatitis. The trial will assess the safety, tolerability, pharmacokinetics, and efficacy of ATI-2138 over a 12-week period, involving approximately 15 subjects in the United States. Aclaris expects topline data to be available in the first half of 2025, highlighting the company's ongoing commitment to addressing unmet needs in immuno-inflammatory diseases.
Read more →ACRSAclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Aclaris Therapeutics will participate in the 2024 Cantor Global Healthcare Conference on September 17, 2024. Members of the management team will engage in a fireside chat to discuss their pipeline and innovations in immuno-inflammatory diseases. The event signifies Aclaris' active involvement in the healthcare sector and commitment to addressing unmet treatment needs in patients. A webcast of the discussion will be available on their website.
Read more →ACRSAclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update -Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis- -Strengthened Balance Sheet Through Sale of Futur
Aclaris Therapeutics has reported its second-quarter financial results for 2024, highlighting the initiation of Phase 2a study activities for ATI-2138 aimed at treating atopic dermatitis. The company has also improved its financial position by selling future OLUMIANT royalties for up to $31.5 million. Despite these advancements, Aclaris faced a net loss of $10.986 million and ongoing high expenses, which have contributed to a decrease in cash reserves. Management remains optimistic about funding operations into 2028 while navigating these financial challenges.
Read more →ACRSAclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million - Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Milli
Aclaris Therapeutics has announced the sale of its future royalty payments and certain milestones from the drug OLUMIANT to OMERS Life Sciences for up to $31.5 million. The deal includes an upfront payment of $26.5 million, with the company positioned to receive an additional $5.0 million contingent on sales milestones. This non-dilutive transaction aims to strengthen Aclaris' balance sheet and provide financial flexibility to support its strategic plans and internal programs. The agreement underscores Aclaris' approach to enhance its capital while continuing to develop its portfolio in immuno-inflammatory diseases.
Read more →ACRSAclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Aclaris Therapeutics announced that Dr. Neal Walker, the Interim President & CEO, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled for June 11, 2024, in Miami, Florida. A webcast of the discussion will be available on the company's website for at least 30 days following the event. Aclaris continues to pursue the development of innovative treatments for immuno-inflammatory diseases through its clinical-stage pipeline.
Read more →ACRSAclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa.
Aclaris Therapeutics, Inc. has reported its financial results for the first quarter of 2024, highlighting a decision to advance its investigational drug ATI-2138 into a Phase 2a trial for moderate to severe atopic dermatitis. The company aims to maintain a capital-efficient approach while navigating financial challenges, including a net loss and reduced resources due to strategic changes. Despite a decrease in cash reserves, Aclaris anticipates lower expenditures moving forward. A conference call is scheduled for later today to provide further updates.
Read more →ACRSAclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
Aclaris Therapeutics, Inc. plans to announce its financial results for the first quarter of 2024 on May 7, 2024, after the market closes. Following the announcement, the management team will conduct a conference call to provide a corporate update, which will be accessible via a live webcast. Aclaris continues to develop drug candidates aimed at treating immuno-inflammatory diseases.
Read more →ACRSAclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update WAYNE, Pa.
Aclaris Therapeutics, Inc. has announced its financial results for the fourth quarter and full year of 2023, reporting a year-over-year increase in licensing revenue while facing a net loss of $88.481 million. As of the end of 2023, the company held $181.9 million in cash and marketable securities, which is lower than the previous year. Dr. Neal Walker's return as CEO is viewed positively as he aims to leverage the company’s expertise in kinase discovery. However, Aclaris remains subject to various operational challenges, including uncertainties in clinical trials and strategic partnerships.
Read more →ACRS▲ +25.5%on this news
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review - Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chai
Aclaris Therapeutics announced leadership changes as Douglas Manion, M.D. steps down as CEO and President. Dr. Neal Walker, the company's Chairman, has been appointed as Interim CEO. Additionally, Aclaris is conducting a strategic business review to optimize capital deployment and maximize shareholder returns. The company reported holding approximately $182 million in cash and marketable securities as of December 31, 2023, but did not specify a timeline for the completion of the review.
Read more →ACRS▼ -21.5%on this newsshared move
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
Aclaris Therapeutics announced top-line results from its Phase 2b trial assessing ATI-1777 for atopic dermatitis. The study demonstrated a statistically significant reduction in the Eczema Area and Severity Index (EASI) score for patients treated with the 2% BID dose after four weeks. Furthermore, the drug showed minimal systemic exposure and was well tolerated with limited adverse events. Aclaris plans to seek a development and commercialization partner and intends to present full results at an upcoming scientific conference.
Read more →ACRS▲ +8.8%on this news
Aclaris Therapeutics Provides Corporate Update
Aclaris Therapeutics has announced key corporate updates, including the publication of Phase 2a trial results for ATI-1777, which showed improvement in atopic dermatitis treatment over four weeks. The company also anticipates topline data from the Phase 2b trial in January 2024. Despite these advancements, Aclaris revealed a significant reduction in workforce by 46% and plans to reassess some of its development programs, indicating challenges in its operational strategy.
Read more →ACRS▲ +8.8%on this news
Aclaris Therapeutics Provides Corporate Update - ATI-1777 Phase 2a Trial Results Published in JID Innovations - - ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 - - Aclaris Announces Reduction in Workfo
Aclaris Therapeutics provided a corporate update highlighting the publication of Phase 2a trial results for ATI-1777 in atopic dermatitis and the commencement of a Phase 2b trial set to report results in January 2024. The company has also announced a workforce reduction of approximately 46% as part of its strategy to streamline operations following changes in development focus. While the progress in clinical trials is promising, the layoffs and discontinuation of another drug candidate pose significant challenges for the organization.
Read more →ACRSAclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
Aclaris Therapeutics has announced an exclusive patent license agreement with Sun Pharmaceutical Industries for the treatment of alopecia areata and androgenetic alopecia. Under the agreement, Aclaris will receive an upfront payment of $15 million along with potential royalties and milestone payments. This marks Aclaris's second out-license of its patent portfolio, reinforcing its strategic approach to partnerships within the biopharmaceutical industry. The license covers the use of deuruxolitinib, Sun Pharma's JAK inhibitor, among other formulations.
Read more →ACRS▼ -86.4%on this news
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
Aclaris Therapeutics announced that its Phase 2b trial of oral zunsemetinib for moderate to severe rheumatoid arthritis failed to meet primary and secondary efficacy endpoints. As a result, the company will discontinue further development of the drug, including halting an ongoing trial for psoriatic arthritis. Despite this setback, Aclaris is focusing on its other pipeline drugs, including ATI-1777 and ATI-2138, with potential updates expected soon.
Read more →ACRS▼ -86.4%on this news
xA9; Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Zunsemetinib (ATI-450) Phase 2b Rheumatoid Arthritis Trial Top-line Results
Aclaris Therapeutics has announced the top-line results from its Phase 2b trial of Zunsemetinib (ATI-450) for rheumatoid arthritis. The report emphasizes the importance of forward-looking statements while acknowledging risks and uncertainties that could affect the future development of their drug candidates. Challenges related to clinical trials and reliance on third parties may impact outcomes. The company’s obligations to update these statements are conditional on new information or future events.
Read more →ACRSAclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update - Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month - - Completion of Enrollment i
Aclaris Therapeutics reported its third quarter 2023 financial results and offered a corporate update highlighting impending topline data from the Phase 2b trial of zunsemetinib for rheumatoid arthritis. The company also announced the completion of enrollment for the ATI-1777 Phase 2b trial in atopic dermatitis, with data expected by year-end. Despite a significant increase in net loss compared to last year and a decrease in total assets, Aclaris reassured investors about sufficient funding to support its operations through 2025.
Read more →ACRSAclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
Aclaris Therapeutics has announced the completion of enrollment in its Phase 2b study of ATI-1777, a topical treatment for atopic dermatitis. The trial aims to evaluate the drug's efficacy, safety, and pharmacokinetics with results expected by the end of 2023. The study involves 250 patients and follows encouraging findings from a prior Phase 2a trial. The developments mark a significant step in Aclaris' efforts to address unmet needs in treating atopic dermatitis.
Read more →ACRS▼ -8.5%on this news
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the 2023 Cantor Global Healthcare Conference, scheduled for September 26, 2023. Members of the management team will join a fireside chat to discuss the company's focus on developing novel drug candidates for immuno-inflammatory diseases. A webcast of the event will be available on Aclaris' website and archived for 30 days. This engagement highlights Aclaris' commitment to addressing patient needs in this therapeutic area.
Read more →ACRSAclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor - Preliminary Data Support Progression to Phase 2a Proof of Conc
Aclaris Therapeutics reported positive outcomes from its Phase 1 Multiple Ascending Dose trial of ATI-2138, leading to plans for a Phase 2a proof of concept study in ulcerative colitis. The trial involved 60 healthy volunteers and found no serious adverse events, with only mild headaches and diarrhea noted. The company is also considering additional trials for other T cell-mediated autoimmune diseases. This progress underscores Aclaris' capabilities in drug development for unmet medical needs in immuno-inflammatory conditions.
Read more →ACRS▼ -7.2%on this news
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update - Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected
Aclaris Therapeutics has reported its financial results for Q2 2023, highlighting the completion of enrollment in the Phase 2b trial for zunsemetinib, targeting rheumatoid arthritis. The company anticipates data read-outs in Q4 2023, building on its clinical development pipeline. Financially, Aclaris holds $210.8 million in cash and equivalents, expected to last through 2025, despite posting a significant net loss of $29.6 million for the quarter. The company continues to explore various indications for its drug candidates and is focused on immuno-inflammatory diseases.
Read more →ACRSAclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)
Aclaris Therapeutics has completed enrollment for its Phase 2b study of oral zunsemetinib (ATI-450) in patients with moderate to severe rheumatoid arthritis. The trial, named ATI-450-RA-202, aims to investigate the drug's efficacy, safety, and tolerability. Aclaris will report preliminary data in the fourth quarter of 2023 and has noted a low rate of trial discontinuations and no concerns raised by its data safety monitoring committee. This investigational drug targets inflammatory cytokines associated with rheumatoid arthritis, and Aclaris is optimistic about its development potential.
Read more →ACRSAclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, is set to participate in two prominent healthcare investor conferences in June 2023. The management team will engage in fireside chats at the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference. These events will enhance the company's visibility in the investment community and provide updates on its innovative drug development efforts for immuno-inflammatory diseases.
Read more →ACRS▼ -6.5%on this news
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update - Management to Host Conference Call at 8:00 AM ET Today - WAYNE, Pa.
Aclaris Therapeutics has reported its financial results for Q1 2023, highlighting progress in clinical-stage development programs. The company is advancing multiple drug candidates toward critical data milestones, particularly zunsemetinib for rheumatoid and psoriatic arthritis, and ATI-2138 for ulcerative colitis. However, the recent trial for zunsemetinib in hidradenitis suppurativa yielded disappointing efficacy results, despite strengthening the safety database. Aclaris has also recently secured funding with $26.7 million from share sales, expected to support operations through 2025.
Read more →ACRSAclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023
Aclaris Therapeutics, Inc. has announced that it will report its first quarter 2023 financial results on May 8, 2023, before the U.S. markets open. The company will also hold a conference call at 8:00 AM ET the same day to discuss these results and provide updates on its ongoing research, including the Phase 2a trial of zunsemetinib in moderate to severe hidradenitis suppurativa. This indicates the company’s commitment to transparency with its stakeholders and ongoing advancement in drug development.
Read more →ACRSxA9; Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) Corporate Overview April 2023 EMPOWERING PATIENTS THROUGH KINOME INNOVATION &#x
Aclaris Therapeutics is advancing its development of ATI-2138, a selective inhibitor targeting T cell signaling, which shows potential for treating autoimmune diseases. The company has completed a Phase 1 Single Ascending Dose Study and initiated a Phase 1 Multiple Ascending Dose Study. Aclaris is also progressing a Phase 2a trial for its investigational compound ATI-1777 in moderate to severe atopic dermatitis, reinforcing its focus on innovative therapies. However, the company faces uncertainties related to clinical trials, reliance on third parties, and broader economic factors.
Read more →ACRSAclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
Aclaris Therapeutics, Inc. announced participation in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023. Members of the Aclaris management team will engage in a fireside chat during the event. The conversation will be accessible via a webcast on Aclaris' website, which will be archived for 30 days. This participation underscores the company's commitment to the autoimmune and inflammatory disease sectors.
Read more →ACRS▼ -44.7%on this news
Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa - Study Did Not Meet Primary or Secondary Efficacy Endpoi
Aclaris Therapeutics announced preliminary results from its 12-week Phase 2a study of zunsemetinib (ATI-450) for moderate to severe hidradenitis suppurativa. The study did not achieve its primary or secondary efficacy endpoints, as the treatment did not significantly reduce inflammatory nodule/abscess counts compared to placebo. Despite this, the safety profile of zunsemetinib was consistent with prior studies, showing that adverse events were mostly mild to moderate. Aclaris aims to explore further data from a Phase 2b study in rheumatoid arthritis.
Read more →ACRSAclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update WAYNE, Pa.
Aclaris Therapeutics announced its financial results for the fourth quarter and full year of 2022, highlighting significant advancements in its clinical development programs. The company is focused on immuno-inflammatory diseases and anticipates multiple data read-outs in 2023, starting with a Phase 2a trial of zunsemetinib next month. Financially, Aclaris had a slight increase in cash and equivalents year-over-year, but reported substantial net losses. The company aims to leverage its kinase-focused drug discovery platform for long-term value.
Read more →ACRSAclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, will participate in the Virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 9:20 AM ET. The management team will conduct a fireside chat, which can be accessed via the Events page on Aclaris' website. Aclaris specializes in developing novel drug candidates for immuno-inflammatory diseases, aiming to address unmet medical needs.
Read more →ACRSxA9; Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2023 Aclaris Therapeutics, Inc. All rights reserved (PP -- US - 0782 1/09) 41 st Annual J.P. Morgan Healthcare Conference January 2
Aclaris Therapeutics has made advancements in its drug development pipeline, notably with ATI-2138 and ATI-1777, which target autoimmune diseases and atopic dermatitis, respectively. The successful completion of Phase 1 studies for these candidates fuels optimism about their therapeutic potential. However, the company acknowledges several risks, including reliance on external parties and uncertainties due to the COVID-19 pandemic that could affect clinical trial outcomes and regulatory submissions.
Read more →ACRS▲ +8.7%on this newsshared move
Aclaris Therapeutics Provides 2023 Outlook
Aclaris Therapeutics, Inc. has provided an optimistic outlook for 2023, with several key data read-outs expected from its clinical programs, including zunsemetinib and ATI-1777. The company is also focused on advancing its earlier stage assets, such as ATI-2138 and ATI-2231, which target significant medical needs in autoimmune diseases and cancer. CEO Douglas Manion highlighted the exciting potential of these developments and noted a corporate presentation scheduled for January 11, 2023, at the J.P. Morgan Healthcare Conference in San Francisco.
Read more →ACRS▼ -7.1%on this news
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pe
Read more →ACRSAclaris Therapeutics Announces Key Leadership Transitions
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board of Directors - Kevin
Read more →ACRSAclaris Therapeutics to Participate in Two November Healthcare Investor Conferences
WAYNE, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the company will participate in two November heal
Read more →ACRSAclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update - Completed Enrollment in Phase 2a Trial of Zunsemetinib in Hidradenitis Suppurativa; Topline Data Expected in Mid-first H
Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update - Completed Enrollment in Phase 2a Trial of Zunsemetinib in Hidradenitis Suppurativa; Topline Data Expected in Mid-first Half of 2023 - Announced Patent License Agreement with Lill
Read more →ACRSAclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has appointed Robert A. Doody Jr. as Vice Pre
Read more →ACRSAclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, CEO of Aclaris, will virtually p
Read more →ACRS▲ +5.3%on this newsshared move
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced a non-exclusive patent license agreement with Eli Lill
Read more →ACRSAclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update Appointed Douglas Manion, M.D., FRCP (C), as President and COO Initiated Phase 2a Study Activities for Psoriatic Arthriti
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update Appointed Douglas Manion, M.D., FRCP (C), as President and COO Initiated Phase 2a Study Activities for Psoriatic Arthritis WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclari
Read more →ACRS▼ -11.6%on this newsshared move
Aclaris Therapeutics Expands Leadership Team
Appoints Douglas Manion, M.D., FRCP (C), as President and COO WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today a
Read more →ACRSAclaris Therapeutics to Participate in the Jefferies Healthcare Conference
WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, wi
Read more →ACRSAclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, wil
Read more →ACRSAclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update Clinical Sites Activated for Phase 2b Trial of ATI-1777 April Capital Raise Extends Cash Runway Through End of 2025 WAYNE,
Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update Clinical Sites Activated for Phase 2b Trial of ATI-1777 April Capital Raise Extends Cash Runway Through End of 2025 WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therape
Read more →ACRSAclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
WAYNE, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO, and Walter Smi
Read more →ACRS▲ +5.2%on this news
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update WAYNE, Pa.
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug c
Read more →ACRSAclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference
WAYNE, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, wi
Read more →ACRSAclaris Therapeutics Provides R&D Update
WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its clinical prog
Read more →ACRSAclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
WAYNE, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, wi
Read more →ACRSxA9; Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP--US-0589 06/21) © Copyright 2021 Aclaris Therapeutics, Inc. All rights
Last Accessed November 23, 2021. 2. Pan s J, et al. Gut. 2017 Jun;66(6):1049-1059. 3. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Last Accessed November 23, 2021. 4. S
Read more →ACRSAclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine
WAYNE, Pa., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the publication of preclinical research of zunsemetini
Read more →ACRSAclaris Therapeutics to Host Virtual R&D Day on December 7, 2021
Investigational New Drug Application for ATI-2138 Allowed WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today annou
Read more →ACRSAclaris Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upco
Read more →ACRS▼ -10.9%on this newsshared move
Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update Investigational New Drug Application for ATI-2138 for the Treatment of Psoriasis Submitted in October 2021 Planning to Ini
Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update Investigational New Drug Application for ATI-2138 for the Treatment of Psoriasis Submitted in October 2021 Planning to Initiate Phase 2b Trial of Zunsemetinib (ATI-450) in Moder
Read more →ACRS▲ +9.8%on this news· ran to +21% by day 3
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the “Settlement Hearing”) w
Read more →ACRS▲ +9.8%on this news· ran to +21% by day 3
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE ACLARIS THERAPEUTICS, INC. DERIVATIVE LITIGATION Lead Case No. 1:19-cv-10641-LJL NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE ACTIO
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE ACTION THIS NOTICE RELATES TO THE PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE LITIGATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS
Read more →ACRSAclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update Public Offering with Net Proceeds of $134.9 Million in June Strengthens Balance Sheet and Extends Cash Runway Through the
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update Public Offering with Net Proceeds of $134.9 Million in June Strengthens Balance Sheet and Extends Cash Runway Through the End of 2024 Positive Preliminary Topline Data for Pha
Read more →ACRSAclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021
WAYNE, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, wi
Read more →ACRSAclaris Announces Pricing of Public Offering of Common Stock
WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,04
Read more →ACRSAclaris Announces Proposed Public Offering of Common Stock WAYNE, Pa.
Aclaris Announces Proposed Public Offering of WAYNE, Pa., June 8, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that i
Read more →ACRSAclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
ATI-1777 Achieved Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach ATI-1777 was Generally Well Tolerated Data Support Progression to Phase 2b Management to Host Conference Call
Read more →ACRSAclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
WAYNE, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, wil
Read more →ACRSAclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis Expected in Second Quarter of 2021 Advancing
Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis Expected in Second Quarter of 2021 Advancing ATI-450 with Planned Initiation of Phase 2b Trial for
Read more →ACRSAclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
Enrollment Completed Data Expected Mid-Year 2021 WAYNE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced th
Read more →ACRSAclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021 ATI-45
Read more →ACRSAclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside
Read more →ACRSxA9; Copyright 2021 Aclaris Therapeutics, Inc. All rights reserved (PP--US-0544 01/21) ATI-450-RA-201 ATI-450-PKPD-102 Preliminary Topline Analyses January 2021 EMPOWERING PATIENTS THROUGH KINOME INNOVATION © Copyri
Data on file. 2. Fortune Business Insights. Accessed January 18, 2021. https://www.fortunebusinessinsights.com/industry-reports/immunology-market-100657. 6 Inflammatory Bowel Disease Ankylosing spondylitis Neutrophilic Dermatoses (Hidradenitis Suppurativa) CAPS Gout Psoriasis Rhe
Read more →ACRSAclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
Durable Clinical Activity over 12 Weeks was Demonstrated Data Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid Arthritis ATI-450, an Investigational Oral MK2 Inhibitor, was Generally Well Tolerated Data Support Progressi
Read more →ACRSAclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside
Read more →ACRSAclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update First Subject Dosed in Phase 2a Trial of ATI-1777, an Investigational Topical "Soft" JAK 1/3 Inhibitor, for the Treatment
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update First Subject Dosed in Phase 2a Trial of ATI-1777, an Investigational Topical "Soft" JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis Initiated Phas
Read more →ACRSAclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
WAYNE, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the first patient has been dosed in Aclaris’ Phas
Read more →ACRSxA9; Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (PP--US-0508 09/20) Company Overview September 2020 EMPOWERING PATIENTS THROUGH
Dillingh M, et al. Front. Immunol. 2016;7(508):1-9. * Data on file. 25 - No serious adverse events or adverse events that led to discontinuation of study medication - All adverse events were mild in severity and did not interfere with everyday activities - A trend of a decrease i
Read more →ACRSAclaris Therapeutics to Present at Upcoming Investor Conferences
WAYNE, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upc
Read more →ACRSAclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatmen
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid Arthritis First Su
Read more →ACRSAclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
WAYNE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that it has submitted an Investigational New Drug (
Read more →ACRSAclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
FDA Allows IND to Study ATI-450 in Hospitalized Patients with COVID-19 Aclaris Supports Investigator-Initiated Clinical Trial Sponsored by the University of Kansas Medical Center ATI-450 Inhibits Multiple Key Inflammatory Cytokines WAYNE, Pa., June 17, 2020 (GLOBE NEWSWIRE) --
Read more →ACRSxA9; Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (PP--US-0484 06/20) ATI-450: A Potential Treatment for Patients with COVID-19 ATI-450, an investigational oral MK2 inhibitor
Vittal R, Fisher A, Gu H, et al. Peptide-Mediated Inhibition of Mitogen-Activated Protein Kinase Activated Protein Kinase 2 Ameliorates Bleomycin-Induced Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2013;49(1):47 57. doi: 10.1165/rcmb.2012-0389OC 23. Liang J, Liu N, Liu X, et a
Read more →ACRSAclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress
WAYNE, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced the publication of an abstract at the 2020 European
Read more →ACRSxA9; Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (PP--US-0480 05/20) Company Overview May 2020 EMPOWERING PATIENTS THROUGH KINOM
J Exp Med. 2018;215(5):1315-1325. 2 Strasser S, et al. Integrative Biology. 2019;11(7):301-314. 0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6 2.8 0 5 10 15 20 Paw Volume - ml Study Day Vehicle CDD450 - 10 MPK CDD450 - 5 MPK CDD110 - 1.5 MPK Oral dosing initiated vehicle ATI-450 IL1 (bone m
Read more →ACRSAclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference
WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present a company overview at the Jefferies Virtual Healthcare Conferenc
Read more →ACRSxA9; Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (XX) © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved (PP--US-0458 05/20) Company Overview May 2020 EMPOWERING PATIENTS THROUGH KINOM
J Exp Med. 2018;215(5):1315-1325. 2 Strasser S, et al. Integrative Biology. 2019;11(7):301-314. 0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6 2.8 0 5 10 15 20 Paw Volume - ml Study Day Vehicle CDD450 - 10 MPK CDD450 - 5 MPK CDD110 - 1.5 MPK Oral dosing initiated vehicle ATI-450 IL1 (bone m
Read more →ACRSAclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights Projected Cash Runway into the First Quarter of 2022 Borrowed $11 Million from Term Loan Facility Wayne, PA
Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights Projected Cash Runway into the First Quarter of 2022 Borrowed $11 Million from Term Loan Facility Wayne, PA - May 7, 2020 (GLOBE NEWSWIRE) - Aclaris Therapeutics, In
Read more →ACRSAclaris Therapeutics Secures $11 Million Term Loan Facility Wayne, PA –
Aclaris Therapeutics Secures $11 Million Term Loan Facility Wayne, PA March 31, 2020 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company, today announced that it has entered into a loan and security agreement with Silicon Valley
Read more →ACRSAclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights  Positive Preliminary Results from Phase 1 Single and Multiple Ascending Dose Trial of ATI
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights Positive Preliminary Results from Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor Projected Cash Runw
Read more →ACRSAclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
WAYNE, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will report financial results for the fourth quarter and full year 2019, Tuesday, February
Read more →ACRSAclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference
WAYNE, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present a company overview at the SVB Leerink 9th Annual Global Healthc
Read more →ACRSxA9; Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2020 Aclaris Therapeutics, Inc. All rights reserved Company Overview January 2020 EMPOWERING PATIENTS THROUGH KINOME INNOVATION © C
J Exp Med. 2018;215(5):1315-1325. 2 Strasser S, et al. Integrative Biology. 2019;11(7):301-314. 0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6 2.8 0 5 10 15 20 Paw Volume - ml Study Day Vehicle CDD450 - 10 MPK CDD450 - 5 MPK CDD110 - 1.5 MPK Oral dosing initiated vehicle ATI-450 IL1 (bone m
Read more →ACRSAclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
• Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6 • Preliminary data support progression to Phase 2a Proof of Concept Trials in Immuno-Inflammatory Diseases WAYNE, Pa., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a phy
Read more →ACRSAclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors Wayne, PA –
Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors Wayne, PA January 8, 2020 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced the appoint
Read more →ACRSxA9; Copyright 2019 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2019 Aclaris Therapeutics, Inc. All rights reserved Company Overview December 2019 EMPOWERING PATIENTS THROUGH KINOME INNOVATION ©
J Exp Med. 2018;215(5):1315-1325. 2 Strasser S, et al. Integrative Biology. 2019;11(7):301-314. 0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6 2.8 0 5 10 15 20 Paw Volume - ml Study Day Vehicle CDD450 - 10 MPK CDD450 - 5 MPK CDD110 - 1.5 MPK Oral dosing initiated vehicle ATI-450 IL1 (bone m
Read more →ACRSxA9; Copyright 2019 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2019 Aclaris Therapeutics, Inc. All rights reserved Company Overview November 2019 EMPOWERING PATIENTS THROUGH KINOME INNOVATION ©
J Exp Med. 2018;215(5):1315-1325. 2Strasser et al. Integrative Biology, in press - Substrate-based kinase activity inference identifies MK2 as driver of colitis. 0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6 2.8 0 5 10 15 20 Paw Volume - ml Study Day Vehicle CDD450 - 10 MPK CDD450 - 5 MPK
Read more →ACRSAclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs  Completed Strategic Review and Announced Refocusing of Resources on Immuno-inflamm
Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs Completed Strategic Review and Announced Refocusing of Resources on Immuno-inflammatory Development Pipeline Divested RHOFADE (oxymetazoline hydr
Read more →ACRSAclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019
WAYNE, Pa., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will report financial results for the third quarter 2019, Thursday, November 7th, after U.
Read more →ACRSAclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)
If approved, A-101 45% Topical Solution would be the first FDA-approved prescription treatment for common warts Highly statistically significant results for the primary efficacy endpoint Highly statistically significant results for all secondary efficacy endpoints Management t
Read more →ACRSACLARIS THERAPEUTICS ANNOUNCES DIVESTITURE OF RHOFADE® Wayne, PA –
ACLARIS THERAPEUTICS ANNOUNCES DIVESTITURE OF RHOFADE Wayne, PA October 10, 2019 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it has divested RHOFADE (oxymetazoline
Read more →ACRSAclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE (oxymetazoline hydrochloride) cream, 1%
WAYNE, Pa., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced today that the company, together with Allergan, Inc., has filed a patent infringement lawsuit in t
Read more →ACRSxA9; Copyright 2019 Aclaris Therapeutics. All rights reserved EMPOWERING PATIENTS THROUGH REVELATIONARY SCIENCE Aclaris Therapeutics Research & Development Day
Seven days after priming: 0 hr: Mice dosed PO with ATX-002 or ATX-025, 30 mg/kg 2 hr: Mice injected intrarectally with 100 ml, 1% OXA 4 hr: Colons harvested, and lysate analyzed cytokines by ELISA (MSD) - 3 cytokines significantly inhibited after oral dosing with compound and OXA
Read more →ACRSAclaris Therapeutics to Hold R&D Day
WAYNE, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will host an R&D day for analysts and investors focused on its pipeline of novel drug ca
Read more →ACRSAclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
Highly statistically significant results at the primary endpoint - statistical significance seen as early as Day 29 Highly statistically significant results on all secondary efficacy endpoints WART-302 is the first of two Phase 3 pivotal trials for the NDA If approved, A-101 4
Read more →ACRSACLARIS THERAPEUTICS ANNOUNCES NEW STRATEGIC DIRECTION · Completion of Strategic Review and Refocusing of Resources on Immuno-Inflammatory Development Pipeline · Actively Seeking a Commercialization Partner for
ACLARIS THERAPEUTICS ANNOUNCES NEW STRATEGIC DIRECTION Wayne, PA September 5, 2019 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the completion of
Read more →ACRSAclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments  Undertaking strategic review of commercial and R&
Aclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments Undertaking strategic review of commercial and R&D assets IND for ATI-450, an investigational compound and oral
Read more →ACRSACLARIS THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District for the Southern District of New York against Aclaris Therapeutics, Inc.
NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased or oth
Read more →ACRSAclaris Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019
WAYNE, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced it will report financial results for the second quarter 2019, Thursday, A
Read more →ACRSAclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint · ATI-501 achieved statistically significant improvement over placebo in several measures o
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint Wayne, PA July 30, 2019 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammator
Read more →ACRSAclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE (Oxymetazoline Hydrochloride) Cream, 1%
Issuance of U.S. Patent No. 10,335,391 Further Strengthens Aclaris’ RHOFADE Patent Portfolio WAYNE, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological disea
Read more →ACRSAclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors Wayne, PA –
Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors Wayne, PA July 3, 2019 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announc
Read more →ACRSAclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
ATI-502 did not achieve statistical superiority at the primary or secondary endpoints due to high rates of disease resolution in vehicle-treated patients WAYNE, Pa., June 26, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical co
Read more →ACRSAclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness) WAYNE, Pa.
Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness) WAYNE, Pa., June 17, 2019 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physi
Read more →ACRSAclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference
WAYNE, Pa., June 14, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that management will present a company overview at the 2019 JMP Securitie
Read more →ACRSxA9; Copyright 2019 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2019 Aclaris Therapeutics, Inc. All rights reserved Company Overview Dr. Neal Walker President and CEO June 2019 EMPOWERING PATIENTS THR
This portfolio also includes an issued patent in Europe for tofacitinib or decernotinib for use in treating hair loss disorders and a pending European application for ruxolitinib or baricitinib to treat hair loss disorders, 3 issued patents in Japan to ruxolitinib, baricitnib, to
Read more →ACRSAclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference
WAYNE, Pa., May 24, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that management will present a company overview at the Jefferies 2019 Glob
Read more →ACRSAclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments  Submitted IND for ATI-450, an oral MK2 inhibitor  RHOFADE net sales of $3.7 m
Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments Submitted IND for ATI-450, an oral MK2 inhibitor RHOFADE net sales of $3.7 million for the first quarter of 2019 Management to Host Conference Ca
Read more →ACRSAclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019
WAYNE, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced it will report financial results for the first quarter 2019, Wednesday, Ma
Read more →ACRSAclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis
WAYNE, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that it has submitted an Investigational New Drug (IND) Application to t
Read more →ACRSAclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata
WAYNE, Pa., April 24, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. P
Read more →ACRSxA9; Copyright 2019 Aclaris Therapeutics, Inc. All rights reserved © Copyright 2019 Aclaris Therapeutics, Inc. All rights reserved Company Overview Dr. Neal Walker President and CEO April 2019 EMPOWERING PATIENTS TH
Aclaris Therapeutics, Inc. Investigational Selective JAK 1/3 Inhibitors Portfolio and IP Estate: ATI-501 JAK1/JAK3 inhibitors Oral treatment for alopecia totalis and alopecia universalis ATI-1777 JAK1/JAK3 inhibitors Soft Topical treatment for atopic dermatitis, alopecia areata,
Read more →ACRSAclaris Therapeutics to Attend Upcoming Investor Conference
WAYNE, Pa., March 27, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced that management will attend the following conference: Management will h
Read more →ACRSAclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments  Product Sales of $3.9 Million for Fiscal Year 2018  Initiates
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments Product Sales of $3.9 Million for Fiscal Year 2018 Initiates Financial Guidance for Full Year 2019 Management to Host Conference C
Read more →ACRSAclaris Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 18, 2019
WAYNE, Pa., March 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced it will report financial results for the fourth quarter and full year 20
Read more →ACRSAclaris Therapeutics Receives European Approvals of ESKATA (hydrogen peroxide) cutaneous solution, 685 mg
WAYNE, Pa., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced that it received approval from the Swedish Medical Products Agency to
Read more →ACRSAclaris Therapeutics to Present Scientific Posters at the 77th Annual Meeting of the American Academy of Dermatology
Phase 2 Clinical Study Results in Treatment of Common Warts Selected for Oral Presentations WAYNE, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that posters summarizing the clinica
Read more →ACRSAclaris Therapeutics to Attend Upcoming Investor Conferences
WAYNE, Pa., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology and immunology, t
Read more →ACRSAclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials · Conference call to be held and accompanying slide deck with photos to be included with Current Report on Form 8-K WAYNE, P
Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials WAYNE, Pa., December 17, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commerci
Read more →ACRSAclaris Therapeutics Closes Acquisition of RHOFADE® (oxymetazoline hydrochloride) cream, 1% from Allergan WAYNE, Pa.
Aclaris Therapeutics Closes Acquisition of RHOFADE (oxymetazoline hydrochloride) cream, 1% from Allergan WAYNE, Pa., December 3, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing,
Read more →ACRSAclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments Management to Host Conference Call at 5:00 PM ET today Wayne, PA –
Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments Management to Host Conference Call at 5:00 PM ET today Wayne, PA November 6, 2018 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatolo
Read more →ACRSAclaris Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018
WAYNE, Pa., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermato
Read more →ACRSAclaris Announces Closing of Public Offering of Common Stock
WAYNE, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient needs in aesthetic and medical
Read more →ACRSAclaris Announces Proposed Public Offering of Common Stock
WAYNE, Pa., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient needs in aesthetic and medical
Read more →ACRSAclaris Therapeutics to Acquire Worldwide Rights to RHOFADE® from Allergan WAYNE, Pa.
Aclaris Therapeutics to Acquire Worldwide Rights to RHOFADE from Allergan WAYNE, Pa., October 15, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative
Read more →ACRSAclaris Therapeutics Announces Poster Presentations at 2018 American Society for Dermatologic Surgery Annual Meeting and Fall Clinical Dermatology Conference
WAYNE, Pa., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatolo
Read more →ACRSAclaris Therapeutics Launches Direct-to-Consumer Campaign for ESKATA (hydrogen peroxide) Topical Solution 40%, (w/w)
ESKATA is the First and Only FDA-Approved Topical Treatment for Raised Seborrheic Keratoses WAYNE, Pa., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializi
Read more →ACRSAclaris Therapeutics Announces Partnership with Harris-Stowe State University to Support Development of Scientists from Underrepresented Minority Groups
WAYNE, Pa., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatolo
Read more →ACRSAclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common Warts
WAYNE, Pa., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermat
Read more →ACRSAclaris Therapeutics to Highlight Drug Discovery Targeting the Human Kinome at 16th Annual Discovery on Target Meeting
WAYNE, Pa., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced that its subsidiary, Confluence Discovery Technologies, Inc., will present two posters at Cambridge Healthtech Institute’s Discovery on Target meeting to be held in Boston from Sept.
Read more →ACRSAclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in the Journal Cancer Research
WAYNE, Pa., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatolo
Read more →ACRSAclaris Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments Management to Host Conference Call at 8:00 AM ET today Wayne, PA –
Aclaris Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments Management to Host Conference Call at 8:00 AM ET today Wayne, PA August 3, 2018 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatolog
Read more →ACRSAclaris Therapeutics to Announce Second Quarter 2018 Financial Results on August 3, 2018
WAYNE, Pa., July 26, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermato
Read more →ACRSAclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata
WAYNE, Pa., June 28, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermato
Read more →ACRSAclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis
WAYNE, Pa., June 26, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermato
Read more →ACRSAclaris Therapeutics Expands Leadership Team, Appointing Dr. David Gordon as Chief Medical Officer
Former Deputy Office Director at the FDA, Elaine Morefield, PhD, also joins Aclaris WAYNE, Pa., June 15, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing inn
Read more →ACRSAclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering ESKATA
WAYNE, Pa., May 30, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatol
Read more →ACRSAclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting
WAYNE, Pa., May 16, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatol
Read more →ACRSAclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting
WAYNE, Pa., May 15, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatol
Read more →ACRSAclaris Therapeutics to Present at the 2018 American Hair Research Summit
WAYNE, Pa., May 11, 2018 (GLOBE NEWSWIRE) -- Paul Changelian, Ph.D., Vice President, Biology, Aclaris Therapeutics, Inc. (NASDAQ:ACRS), will speak at the 2018 American Hair Research Summit on “Preclinical to Clinical Translation of JAK Kinase Inhibitors" on May 15. The meeting is
Read more →ACRSAclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments · Management to Host Conference Call at 5:00 PM ET today Wayne, PA –
Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments Wayne, PA May 8, 2018 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying,
Read more →ACRSAclaris Therapeutics Announces Availability of ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w)
MALVERN, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that ESKATA™ is now available for purchase by dermatologists in the United States. ESKATA is the first and only FDA-approved top
Read more →ACRSAclaris Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
WAYNE, Pa., April 24, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermat
Read more →ACRSAclaris Therapeutics Announces Appointment of Bryan Reasons as a Director and Chairman of the Audit Committee WAYNE, Pa.
Aclaris Therapeutics Announces Appointment of Bryan Reasons as a Director and Chairman of the Audit Committee WAYNE, Pa., April 24, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developi
Read more →ACRSAclaris Therapeutics Announces First Patient Dosed in a Pilot Study with ATI-502 Topical in Patients with Androgenetic Alopecia
WAYNE, Pa., April 23, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermat
Read more →ACRSAclaris Therapeutics Partners with Cipher Pharmaceuticals to seek regulatory approval and commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses in Canada
The agreement will expand the availability of the first and only U.S. FDA-approved prescription product for the treatment of raised seborrheic keratoses (SKs) WAYNE, Pa., April 06, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmace
Read more →ACRSAclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine
WAYNE, Pa., March 20, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermat
Read more →ACRSAclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts
Primary, secondary, and exploratory endpoints of Phase 2 trial met during 8-week treatment period After treatment completed, greater improvement vs. placebo observed in 3-month post-treatment follow-up evaluation If approved, A-101 45% would be the first FDA-approved treatment
Read more →ACRSAclaris Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Clinical and Commercial Developments · Initiates Financial Guidance for Full Year 2018 · Management to Hos
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Clinical and Commercial Developments Wayne, PA March 12, 2018 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committe
Read more →ACRSAclaris Therapeutics Announces Issuance of U.S. Patent Covering a JAK Inhibitor for Treating Hair Loss Disorders
Issuance of U.S. Patent No. 9,895,301 Further Bolsters Aclaris’ Intellectual Patent Portfolio WAYNE, Pa., March 09, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercial
Read more →ACRSAclaris Therapeutics to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results on March 12, 2018
WAYNE, Pa., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and
Read more →ACRSAclaris Therapeutics to Present Data on ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) at the 2018 American Academy of Dermatology Annual Meeting
ESKATA™ received FDA approval for the treatment of raised seborrheic keratoses (SKs) in December 2017 WAYNE, Pa., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that data will be presente
Read more →ACRSAclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts
Highly statistically significant results on all primary and secondary endpoints Statistical significance seen as early as day 28, after 4 weeks of treatment in WART-203 If approved, A-101 45% would be the first FDA approved treatment for common warts MALVERN, Pa., Jan. 08, 201
Read more →ACRSCompany Overview Dr. Neal Walker President and CEO January 2018 © Copyright 2018 Aclaris Therapeutics. All rights reserved. A-1 Illuminating Science Empowering Patients Any statements contained in this presentation
Launch Expected EU Approval A-101 Common Warts Phase 2 Data Initiate Phase 3 trial(s) Phase 3 Data File NDA ATI-50001/ATI-50002 (JAK Inhibitor) Initiate Phase 2 (ATI-50001) AA Trial Phase 2 (ATI-50001) AA Dose Range Data Phase 2 (ATI-50002) AA PK/PD Data Phase 2 (ATI-50002) AA Ey
Read more →ACRSAclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo
MALVERN, Pa., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical an
Read more →ACRSAclaris Therapeutics Receives FDA Approval for ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) for Treatment of Raised Seborrheic Keratoses (SKs) ESKATA™ is the First and Only FDA-Approved Topical,
Aclaris Therapeutics Receives FDA Approval for ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) for Treatment of Raised Seborrheic Keratoses (SKs) ESKATA is the First and Only FDA-Approved Topical, Non-invasive Treatment for Raised SKs Management to Hold Conference Call
Read more →ACRSAclaris Therapeutics Presents New Data at American College of Rheumatology Annual Meeting For ATI-450, a MK2 pathway Inhibitor
MALVERN, Pa., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical an
Read more →ACRSAclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly
MALVERN, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical an
Read more →ACRSAclaris Therapeutics Reports Third Quarter 2017 Financial Results Management to Host Conference Call at 8:00 AM ET today Malvern, PA –
Aclaris Therapeutics Reports Third Quarter 2017 Financial Results Management to Host Conference Call at 8:00 AM ET today Malvern, PA November 7, 2017 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on identifying
Read more →ACRSAclaris Therapeutics to Announce Third Quarter 2017 Financial Results on November 7, 2017
MALVERN, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its third quarter financial results before the market open on November 7, 2017 Management will conduct a conference call at 8:00 AM ET t
Read more →ACRSAclaris Therapeutics Announces the Allowance of a U.S. Patent Application and Issuance of a Japanese Patent Covering Tofacitinib for Treating Hair Loss Disorders
MALVERN, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and
Read more →ACRSAclaris Therapeutics R&D and Investor Day
Approval Expected U.S. Launch A-101 Common Warts Initiate Two Additional Phase 2 Trials Additional Phase 2 data ATI-50001/ATI-50002 Alopecia Areata Initiate Phase 2 (ATI-50001) Submit IND (ATI-50002) Initiate Phase 2 (ATI-50002) ATI-50001/ATI-50002 Vitiligo Initiate Phase 2 (ATI-
Read more →ACRSAclaris Therapeutics to Host R&D and Investor Event on October 4, 2017 in New York
MALVERN, Pa., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical a
Read more →ACRSAclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis
MALVERN, Pa., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that results from a Phase 2 clinical trial evaluating two concentrations (40% and 32.5%) of its drug candidate A-101 for the t
Read more →ACRSAclaris Therapeutics Announces Issuance of Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders
MALVERN, Pa., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical an
Read more →ACRSAclaris Announces Appointment of Andrew Schiff to Board of Directors Malvern, PA –
Aclaris Announces Appointment of Andrew Schiff to Board of Directors Malvern, PA August 9, 2017 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differ
Read more →ACRSEx_99.1 Aclaris Therapeutics Reports Second Quarter 2017 Financial Results Management to Host Conference Call at 8:30 AM ET today Malvern, PA –
Aclaris Therapeutics Reports Second Quarter 2017 Financial Results Management to Host Conference Call at 8:30 AM ET today Malvern, PA August 8, 2017 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company, today announced financ
Read more →ACRSAcrs_Ex 99.1 Aclaris Therapeutics Acquires Confluence Life Sciences, Inc. Expands pipeline of medicines for the potential treatment of patients with autoimmune disorders Management to Host Conference Call at 8:30 AM ET t
Aclaris Therapeutics Acquires Confluence Life Sciences, Inc. Expands pipeline of medicines for the potential treatment of patients with autoimmune disorders Management to Host Conference Call at 8:30 AM ET today Malvern, PA, August 8, 2017 (GLOBE NEWSWIRE) Aclaris Therapeutics
Read more →ACRSAclaris Therapeutics Reports Second Quarter 2017 Financial Results
MALVERN, Pa., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced financial results for the second quarter of 2017 and provided an update on its clinical development programs. “The second quar
Read more →ACRSAclaris Therapeutics Acquires Confluence Life Sciences, Inc.
Expands pipeline of medicines for the potential treatment of patients with autoimmune disorders Management to Host Conference Call at 8:30 AM ET today MALVERN, Pa., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (“Aclaris”) (NASDAQ:ACRS), a dermatologist-led, biop
Read more →ACRSAclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis
MALVERN, Pa., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and
Read more →ACRSAclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata
MALVERN, Pa., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical an
Read more →ACRSAclaris Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
MALVERN, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its first quarter financial results before the market open on August 8, 2017 Management will conduct a conference call at 8:30 AM ET tha
Read more →ACRSAclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts
MALVERN, Pa., June 29, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and ae
Read more →ACRSAclaris Therapeutics Announces Issuance of New U.S. Patent For A-101 Topical Solutions
MALVERN, Pa., June 13, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biotechnology company focused on developing innovative products in medical and aesthetic dermatology, today announced that the United States Patent and Trademark Office
Read more →ACRSAclaris Therapeutics Reports First Quarter 2017 Financial Results Management to Host Conference Call at 4:30 PM ET today Malvern, PA –
Aclaris Therapeutics Reports First Quarter 2017 Financial Results Management to Host Conference Call at 4:30 PM ET today Malvern, PA May 9, 2017 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biotechnology company, today announced financial resu
Read more →ACRSAclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
MALVERN, Pa., May 09, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Due to technical difficulties experienced by NASDAQ during today’s call, management has rescheduled its conference call for 6:00 PM ET today to discuss the Company’s financial results and pro
Read more →ACRSAclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis
MALVERN, Pa., May 05, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aest
Read more →ACRSAclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution
MALVERN, Penn., April 26, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biotechnology company focused on defining innovative therapies in medical and aesthetic dermatology, today announced that it has received a Notice of Allowance from t
Read more →ACRSAclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting
MALVERN, Pa., April 24, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company focused on defining new standards of care in medical and aesthetic dermatology, today announced it will sponsor a symposium on Janus Kinase (JAK) i
Read more →ACRSAclaris Therapeutics Announces Notice of Allowance for Two U.S. Patent Applications Covering Baricitnib and Decernotinib, Respectively, for Hair Loss Disorders
MALVERN, Pa., April 04, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biotechnology company focused on defining new standards of care in medical and aesthetic dermatology, today announced that Columbia University has received a Notice of
Read more →ACRSAclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update -- Provides Update on Clinical and Other Developments -- Initiates Financial Guidance for Full Year 2017 -- Management to Host Conference Call at 8:00 a.m. ET today
Read more →ACRSAclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis – a Common Skin Condition
MALVERN, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biotechnology company focused on defining new standards of care in medical and aesthetic dermatology, today announced it has submitted a New Drug Application (NDA) to th
Read more →ACRSAclaris Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017
MALVERN, Pa., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its fourth quarter financial results before the market opens on March 15, 2017 Management will conduct a conference call at 8:00 a.m. ET
Read more →ACRSAclaris Announces Appointment of Andrew Powell to Board of Directors Malvern, PA –
Aclaris Announces Appointment of Andrew Powell to Board of Directors Malvern, PA January 26, 2017 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage dermatologist-led pharmaceutical company, today announced the appointment of Andrew Powell to the Aclari
Read more →ACRSAclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors
MALVERN, Pa., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage dermatologist-led pharmaceutical company, today announced the appointment of Andrew Powell to the Aclaris Board, effective January 25th, 2017. Andrew Powell has more than 2
Read more →ACRSAclaris to Present at 35th Annual J.P. Morgan Healthcare Conference
MALVERN, Pa., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led clinical-stage pharmaceutical company focused on defining new standards of care in medical and aesthetic dermatology, today announced that it plans to present at the 35th
Read more →ACRSAclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis
MALVERN, Pa., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), today announced that its Investigational New Drug (IND) Application for ATI-50001, an orally administered investigational Janus Kinase (JAK) inhibitor, for the potential treatment of alopeci
Read more →ACRSAclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition Pivotal Data Show Topical Treatment Delivered Statistically Significant Re
Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition Pivotal Data Show Topical Treatment Delivered Statistically Significant Results, Meeting All Primary and Secondary Endpoints Aclar
Read more →ACRSRelease Aclaris Therapeutics Reports Third Quarter 2016 Financial Results Management to Host Conference Call at 8:30 a.m. ET today Malvern, PA –
Aclaris Therapeutics Reports Third Quarter 2016 Financial Results Management to Host Conference Call at 8:30 a.m. ET today Malvern, PA November 3, 2016 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage specialty pharmaceutical company, today announced
Read more →ACRSAclaris Therapeutics Reports Third Quarter 2016 Financial Results
MALVERN, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced financial results for the third quarter and nine months ended September 30, 2016 and provided an update on its clinical dev
Read more →ACRSAclaris Therapeutics Submits Investigational New Drug Application for ATI-50001 to Treat Alopecia Universalis and Alopecia Totalis
MALVERN, Pa., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for its drug candidate ATI-50001 for the treatment of alope
Read more →ACRSAclaris Therapeutics Honored as One of the Best Places to Work in Pennsylvania
MALVERN, Pa., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc., (NASDAQ:ACRS), a dermatologist-led, specialty pharmaceutical company focused on the development of medical and aesthetic dermatology treatments, has been named one of the Best Places to Work in PA for 201
Read more →ACRSAclaris Therapeutics to Announce Third Quarter 2016 Financial Results on November 3, 2016
MALVERN, Pa., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, will release its third quarter financial results before the market opens on Thursday, November 3, 2016. Management will conduct a conferen
Read more →ACRSxA9; Copyright 2016 Aclaris Therapeutics. All rights reserved. A-1 Company Overview 1 Dr. Neal Walker President and CEO September 2016 This presentation contains forward-looking statements, including statements regarding
Androgenic Alopecia. 2 Bergeson, L. The Truth About Hair Loss and Baldness Cures. 11.08.2014. 3 Fitzpatrick T., et al. Vitiligo Facts. American Vitiligo Research Foundation Inc. September 2016 Milestone 2016 2017 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 A-101 SK Phase 3 Trials Initiated Phase 3 D
Read more →ACRSAclaris Therapeutics to Present at the Morgan Stanley 2016 Healthcare Conference
MALVERN, Pa., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that Dr. Neal Walker, President & Chief Executive Officer, will present at the Morgan Stanley 2016 Global Healthcare Confe
Read more →ACRSAclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
MALVERN, Pa., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced positive results from its Phase 2 clinical trial (WART-201), of A-101 Topical solution (A-101) for the treatment of common
Read more →ACRSAclaris Therapeutics Reports Second Quarter 2016 Financial Results Management to Host Conference Call at 8:30 a.m. ET today Malvern, PA –
Aclaris Therapeutics Reports Second Quarter 2016 Financial Results Management to Host Conference Call at 8:30 a.m. ET today Malvern, PA August 11, 2016 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage specialty pharmaceutical company, today announced
Read more →ACRSAclaris Announces Appointment of Bill Humphries to Board of Directors Malvern, PA – August 4 , 2016 (GLOBE NEWSWIRE) – Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage specialty pharmaceutical co
Aclaris Announces Appointment of Bill Humphries to Board of Directors Malvern, PA August 4, 2016 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage specialty pharmaceutical company, today announced the appointment of Bill Humphries, the President and Ch
Read more →ACRSAclaris Therapeutics to Announce Second Quarter 2016 Financial Results on August 11, 2016
MALVERN, Pa., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, will release its second quarter financial results before the market opens on Thursday, August 11, 2016. Management will conduct a conferen
Read more →ACRSAclaris Therapeutics, Inc. (Nasdaq: ACRS) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, July 25, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage specialty pharmaceutical company, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Dr. Neal Walker, President and CEO, will ring the Closing Bell.
Read more →ACRSAclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis (SK); Provides Update on Clinical Programs
MALVERN, Pa., July 25, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced the completion of patient enrollment in its two Phase 3 pivotal clinical trials and its Phase 3 open-label safety trial of
Read more →ACRSAclaris Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
MALVERN, Pa., July 05, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that Dr. Neal Walker, President & Chief Executive Officer, will present at Cantor Fitzgerald’s 2nd Annual Healthcare Confer
Read more →ACRSAclaris Therapeutics to Present at Upcoming Investor Conferences in June
MALVERN, Pa., May 31, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that Dr. Neal Walker, President & Chief Executive Officer, will present at three upcoming investor conferences in June. Jef
Read more →ACRSAclaris Therapeutics Announces $20.0 Million Private Placement
MALVERN, Pa., May 27, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, announced today that it has entered into a stock purchase agreement with a group of institutional accredited investors for the private place
Read more →ACRSAclaris Therapeutics Reports First Quarter 2016 Financial Results Management to Host Conference Call at 8:30 a.m. ET today Malvern, PA –
Aclaris Therapeutics Reports First Quarter 2016 Financial Results Management to Host Conference Call at 8:30 a.m. ET today Malvern, PA May 11, 2016 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage specialty pharmaceutical company, today announced fin
Read more →ACRSAclaris Therapeutics, Inc. Appoints Kevin Scott as Vice President of Sales
MALVERN, Pa., May 05, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that it has appointed Kevin Scott, an experienced sales executive within the field of dermatology, as Vice President of Sale
Read more →ACRSAclaris Therapeutics to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference
MALVERN, Pa., May 02, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that Dr. Neal Walker, President & Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare
Read more →ACRSAclaris Therapeutics to Announce First Quarter 2016 Financial Results on May 11, 2016
MALVERN, Pa., April 26, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, will release its first quarter financial results before the market opens on Wednesday, May 11, 2016. Management will conduct a conference
Read more →ACRSAclaris Therapeutics Acquires Worldwide Rights to Compounds and Key Intellectual Property for Potential Treatment for Hair Loss Malvern, PA.
Aclaris Therapeutics Acquires Worldwide Rights to Compounds and Key Intellectual Property for Potential Treatment for Hair Loss Malvern, PA. March 28, 2016 (GLOBE NEWSWIRE) - Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical stage specialty pharmaceutical company, today annou
Read more →ACRSAclaris Therapeutics Reports Fourth Quarter and Full Year 2015 Operating and Financial Results Management to Host Conference Call at 4:30 p.m. ET today Malvern, PA –
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2015 Operating and Financial Results Management to Host Conference Call at 4:30 p.m. ET today Malvern, PA March 23, 2016 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage specialty pharmaceutic
Read more →ACRSAclaris Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results on March 23, 2016
MALVERN, Pa., March 17, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, will release its fourth quarter and full year 2015 financial results after the market close on Wednesday, March 23, 2016. Management will
Read more →ACRSAclaris Therapeutics to Present at the 2016 Leerink Partners Annual Global Healthcare Conference
MALVERN, Pa., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that Dr. Neal Walker, President & Chief Executive Officer, will present at the 2016 Leerink Partners Annual Global Healthca
Read more →ACRSAclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis
MALVERN, Pa., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), today announced the initiation of two Phase 3 clinical trials to evaluate A-101 Topical Solution for the treatment of seborrheic keratosis (SK). The two Phase 3 clinical trials will evaluat
Read more →ACRSAclaris Therapeutics, Inc. Added to Russell 2000 Index
MALVERN, Pa., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty dermatology company, today announced that it has been selected for addition to the Russell 2000® and Russell 3000® Indexes as part of Russell Investments' annual r
Read more →ACRSAclaris Therapeutics, Inc. Appoints Brett Fair as Senior Vice President of Commercial Operations
MALVERN, Pa., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), today announced that it has appointed Brett Fair, an experienced executive within the field of dermatology, as Senior Vice President of Commercial Operations. Mr. Fair brings more than 18 y
Read more →ACRSAclaris Therapeutics Initiates Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
MALVERN, Pa., Dec. 7, 2015 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) today announced that it has initiated a Phase 2 clinical trial to evaluate its investigational drug, A-101 Topical Solution, for the treatment of common warts (verruca vulgaris). This double-
Read more →ACRSAclaris Therapeutics Reports Third Quarter 2015 Financial Results Malvern, PA
Aclaris Therapeutics Reports Third Quarter 2015 Financial Results Malvern, PA November 18, 2015 (GLOBE NEWSWIRE) Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage specialty pharmaceutical company, today announced financial results for the third quarter ended September
Read more →ACRSAclaris Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
MALVERN, Pa., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS) today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a price to the public of $11.00 per share, which includes the exercise in full by the und
Read more →ACRSAclaris Announces Pricing of Initial Public Offering
MALVERN, Pa., Oct. 6, 2015 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share. The shares have been approved for listing on The NASDAQ Globa
Read more →Competitive Position
How ACRS ranks across every disease it competes inCompetitive Position is a premium feature
See how ACRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial